iTeos Therapeutics Inc.: iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
- Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens - First-in-class program targeting a new mechanism of action in
10.05.2023 - – Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine pathway, EOS-984, is expected to . Seite 1